4000 Background: Cetuximab in combination with irinotecan-based regimens has proven
activity in previously-treated patients (pts) with mCRC. The present trial investigated the …

PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant
benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated …

… myelotoxicity with increased frequency of neutropenia and thrombocytopenia in this phase
III study, similar to what we reported in our phase II study ( 22 ) . However, in the present …

… However, there are currently no published randomized studies on the use of FOLFIRI in
the … In the present study, we report the results from a multicenter, randomized, phase III trial …

… The study design has been published previously. Briefly, MMY-3021 was an open-label,
randomized, non-inferiority phase III study that enrolled patients at 53 sites in Europe, Asia and …

… The Southwest Oncology Group 13 performed a large randomized phase II trial with several
infusional FU regimens. Continuous infusion of 200 mg/m 2 FU per day was used alone or …

LBA148 Background: nab-Paclitaxel (nab-P, 130 nm albumin-bound paclitaxel) provides
tumor selective localization via transcytosis across the endothelium, potential tumor uptake via …

A total of 307 patients with superficial measurable tumors were registered on a Radiation
Therapy Oncology Group (RTOG) protocol involving fractionated radiation therapy, either alone …

We report the results of a prospective study in patients more than 65 years of age in whom
two different therapeutic strategies were compared: immediate intensive-induction …

4506 Background: The role of radiation therapy (RT) as part of treatment for pancreatic cancer
is uncertain in the post-gemcitabine era. The primary endpoint of this trial was to evaluate …